Actinium Pharmaceuticals IncNYSE American:ATNM
- LAST PRICE6.9700
- TODAY'S CHANGE (%)-0.3100 (-4.2582%)
- Bid / Lots6.9200/ 1
- Ask / Lots7.1500/ 1
- Open / Previous Close7.2400 / 7.2800
- Day Range
- 52 Week Range
- Volume175,161
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ATNM |
|---|---|---|
| 09:32 ET | 5358 | 7.27 |
| 09:36 ET | 400 | 7.125 |
| 09:41 ET | 847 | 7 |
| 09:43 ET | 300 | 7 |
| 09:45 ET | 505 | 6.9501 |
| 09:48 ET | 390 | 7.015 |
| 09:50 ET | 1242 | 7 |
| 09:52 ET | 436 | 6.9875 |
| 09:54 ET | 2100 | 6.9999 |
| 09:56 ET | 600 | 7.04 |
| 09:57 ET | 145 | 7.02 |
| 10:01 ET | 100 | 7.03 |
| 10:03 ET | 499 | 7.0462 |
| 10:06 ET | 100 | 7.04 |
| 10:08 ET | 2548 | 7.07 |
| 10:15 ET | 141 | 7.0665 |
| 10:21 ET | 456 | 7.07 |
| 10:24 ET | 1711 | 7.035 |
| 10:26 ET | 517 | 7 |
| 10:28 ET | 100 | 6.98 |
| 10:30 ET | 382 | 6.981 |
| 10:32 ET | 600 | 7.01 |
| 10:33 ET | 2877 | 7.01 |
| 10:37 ET | 498 | 6.96 |
| 10:39 ET | 100 | 6.97 |
| 10:46 ET | 716 | 6.943 |
| 10:50 ET | 4614 | 6.96 |
| 10:53 ET | 100 | 6.95 |
| 10:55 ET | 200 | 6.945 |
| 10:57 ET | 500 | 6.9301 |
| 11:00 ET | 200 | 6.95 |
| 11:02 ET | 600 | 6.925 |
| 11:04 ET | 295 | 6.9 |
| 11:06 ET | 1286 | 6.9001 |
| 11:08 ET | 1004 | 6.93 |
| 11:11 ET | 12079 | 6.84 |
| 11:13 ET | 500 | 6.85 |
| 11:15 ET | 573 | 6.85 |
| 11:18 ET | 100 | 6.81 |
| 11:20 ET | 600 | 6.88 |
| 11:24 ET | 348 | 6.85 |
| 11:27 ET | 100 | 6.85 |
| 11:29 ET | 300 | 6.8499 |
| 11:31 ET | 400 | 6.85 |
| 11:33 ET | 1517 | 6.83 |
| 11:38 ET | 3201 | 6.93 |
| 11:40 ET | 2200 | 6.92 |
| 11:44 ET | 150 | 6.9495 |
| 11:45 ET | 100 | 6.96 |
| 11:47 ET | 150 | 6.94 |
| 11:49 ET | 400 | 6.96 |
| 11:54 ET | 275 | 6.92 |
| 11:56 ET | 100 | 6.97 |
| 11:58 ET | 100 | 6.97 |
| 12:02 ET | 923 | 6.91 |
| 12:05 ET | 100 | 6.905 |
| 12:09 ET | 2698 | 6.91 |
| 12:12 ET | 1220 | 6.94 |
| 12:14 ET | 380 | 6.9351 |
| 12:16 ET | 100 | 6.8801 |
| 12:18 ET | 100 | 6.91 |
| 12:20 ET | 500 | 6.8914 |
| 12:27 ET | 820 | 6.88 |
| 12:30 ET | 1045 | 6.915 |
| 12:32 ET | 2200 | 6.9395 |
| 12:34 ET | 100 | 6.89 |
| 12:38 ET | 4445 | 6.84 |
| 12:39 ET | 100 | 6.81 |
| 12:41 ET | 650 | 6.825 |
| 12:43 ET | 398 | 6.8 |
| 12:45 ET | 2264 | 6.7501 |
| 12:48 ET | 400 | 6.75 |
| 12:50 ET | 3697 | 6.835 |
| 12:52 ET | 2293 | 6.88 |
| 12:54 ET | 990 | 6.85 |
| 12:56 ET | 139 | 6.845 |
| 12:57 ET | 100 | 6.8 |
| 12:59 ET | 4000 | 6.8532 |
| 01:01 ET | 700 | 6.82 |
| 01:03 ET | 822 | 6.87 |
| 01:10 ET | 900 | 6.85 |
| 01:15 ET | 600 | 6.85 |
| 01:19 ET | 179 | 6.85 |
| 01:21 ET | 100 | 6.845 |
| 01:28 ET | 1399 | 6.92 |
| 01:30 ET | 100 | 6.905 |
| 01:32 ET | 500 | 6.9064 |
| 01:37 ET | 900 | 6.9024 |
| 01:39 ET | 381 | 6.8801 |
| 01:42 ET | 350 | 6.9041 |
| 01:48 ET | 200 | 6.9 |
| 01:53 ET | 600 | 6.9 |
| 01:55 ET | 557 | 6.9 |
| 01:57 ET | 100 | 6.85 |
| 02:00 ET | 466 | 6.9 |
| 02:06 ET | 101 | 6.85 |
| 02:08 ET | 100 | 6.86 |
| 02:09 ET | 200 | 6.86 |
| 02:15 ET | 200 | 6.875 |
| 02:18 ET | 300 | 6.89 |
| 02:20 ET | 200 | 6.88 |
| 02:22 ET | 1000 | 6.89 |
| 02:24 ET | 100 | 6.88 |
| 02:26 ET | 319 | 6.88 |
| 02:27 ET | 100 | 6.87 |
| 02:38 ET | 1000 | 6.885 |
| 02:40 ET | 100 | 6.87 |
| 02:42 ET | 300 | 6.886 |
| 02:47 ET | 2778 | 6.86 |
| 02:51 ET | 600 | 6.855 |
| 02:54 ET | 300 | 6.875 |
| 02:58 ET | 1000 | 6.86 |
| 03:00 ET | 900 | 6.8608 |
| 03:03 ET | 800 | 6.86 |
| 03:05 ET | 638 | 6.87 |
| 03:09 ET | 1600 | 6.91 |
| 03:14 ET | 700 | 6.9 |
| 03:16 ET | 200 | 6.95 |
| 03:18 ET | 100 | 6.92 |
| 03:20 ET | 100 | 6.95 |
| 03:21 ET | 400 | 6.95 |
| 03:25 ET | 1634 | 6.97 |
| 03:30 ET | 100 | 6.97 |
| 03:32 ET | 200 | 6.98 |
| 03:34 ET | 800 | 6.95 |
| 03:36 ET | 200 | 6.95 |
| 03:39 ET | 100 | 6.95 |
| 03:41 ET | 422 | 7 |
| 03:43 ET | 4071 | 6.98 |
| 03:48 ET | 100 | 6.9573 |
| 03:50 ET | 3425 | 6.91 |
| 03:56 ET | 619 | 6.99 |
| 03:57 ET | 650 | 6.95 |
| 03:59 ET | 17602 | 6.97 |
Jun 18, 2024
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions, from 8:46AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:46AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 17, 2024
DJ Actinium Pharmaceuticals Price Target Maintained With a $50.00/Share by HC Wainwright & Co., from 10:55AM ET on Monday Jun 17, 2024 by Dow Jones
10:55AM ET on Monday Jun 17, 2024 by Dow JonesAcute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase, from 9:45AM ET on Monday Jun 17, 2024 by Dow Jones
9:45AM ET on Monday Jun 17, 2024 by Dow JonesAcute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies, from 9:00AM ET on Monday Jun 17, 2024 by Dow Jones
9:00AM ET on Monday Jun 17, 2024 by Dow JonesBiopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML), from 8:46AM ET on Monday Jun 17, 2024 by Dow Jones
8:46AM ET on Monday Jun 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Actinium Pharmaceuticals Inc | 207.6M | -4.1x | --- |
Greenwich Lifesciences Inc | 215.2M | -23.2x | --- |
Fractyl Health Inc | 212.7M | -2.6x | --- |
Rezolute Inc | 212.2M | -3.6x | --- |
ATAI Life Sciences NV | 212.6M | -5.3x | --- |
ESSA Pharma Inc | 222.7M | -8.0x | --- |
Company Information
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Contact Information
- Headquarters
- 100 Park Ave., 23Rd FloorNEW YORK, NY, United States 10017
- Phone
- 646-677-3870
- Fax
- 845-818-3588
Executives
- Chairman of the Board, Chief Executive Officer
- Sandesh Seth
- Chief Financial Officer
- Steve O'Loughlin
- Chief Business Officer
- Lynn Bodarky
- Independent Director
- Jeffrey Chell
- Lead Independent Director
- C. David Nicholson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $207.6M |
|---|---|
Revenue (TTM) | $81.0K |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.20 |
EPS | $-1.72 |
Book Value | $1.32 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | 2,562.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -61,645.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
